Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2026)
Scynexis' (SCYX) quarterly Amortization of Deferred Charges came in at $87000.0 in Q4 2025, up 108.79% YoY from $41669.1 in Q4 2024, and up 12.99% on a QoQ basis from $77000.0 in Q1 2025.
Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 12 years of Amortization of Deferred Charges data on file, last reported at $87000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 108.79% year-over-year to $87000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $87000.0 (up 270.59% YoY) and the FY2025 annual result came in at $326000.0, up 19.85% from the prior year.
- Amortization of Deferred Charges advanced to $87000.0 in Q4 2025, from $77000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $2.8 million in Q4 2023 to a low of -$990000.0 in Q4 2024.
- A 5-year average of $440000.0 and a median of $375000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 706.12% — and 2024, when it sank 135.04%.
- Tracing SCYX's Amortization of Deferred Charges over 5 years: stood at $49000.0 in 2021, then soared by 706.12% to $395000.0 in 2022, then soared by 615.19% to $2.8 million in 2023, then slumped by 135.04% to -$990000.0 in 2024, then jumped by 108.79% to $87000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $87000.0 (Q4 2025), $77000.0 (Q1 2025), and -$990000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Dec 31, 2024 | -990,000.00 |
| Dec 31, 2024 | -990,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 2.83 Mn |
| Dec 31, 2023 | 2.83 Mn |
| Sep 30, 2023 | 360,000.00 |
| Sep 30, 2023 | 360,000.00 |
| Jun 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 2.00 Mn |